<DOC>
	<DOCNO>NCT01110902</DOCNO>
	<brief_summary>The study ass efficacy , safety tolerability 0.5 mg/day 1 mg/day sublingual ( tongue ) formulation agomelatine patient Major Depressive Disorder . This study include 8-week double-blind phase .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Agomelatine Sublingual Tablets Treatment Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Patients diagnosis MDD , single recurrent episode , accord DSMIV criterion . Current episode ≥4 week . CGISeverity score ≥4 Screening Baseline . History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , eat disorder ( current previous one year ) , obsessivecompulsive disorder . Any current Axis I disorder MDD focus treatment . Substance alcohol abuse last 30 day , dependence last 6 month . Concomitant psychotropic medication , include herbal preparation melatonin . Psychotherapy type . Prior exposure agomelatine . Female patient childbearing potential use effective contraception . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Agomelatine</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>depression</keyword>
</DOC>